Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
INmune Bio, Inc. (INMB) had Normalized Pre-Tax Income of $-1.27M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-1.27M |
|
-- |
|
-- |
|
$1.48M |
|
$-1.48M |
|
$0.20M |
|
$-1.27M |
|
|
Normalized Pre-Tax Income |
$-1.27M |
$-1.27M |
|
$-1.27M |
|
$-1.27M |
|
$-1.27M |
|
$-1.48M |
|
$-1.41M |
|
26.72M |
|
26.72M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$23.80M |
|
$1.26M |
|
$3.05M |
|
$26.84M |
|
$5.89M |
|
-- |
|
$0.59M |
|
$6.48M |
|
$20.36M |
|
$20.36M |
|
$20.36M |
|
27.65M |
|
| Cash Flow Statement Financials | |
$-6.58M |
|
$-0.43M |
|
$0.75M |
|
$24.75M |
|
$18.41M |
|
$-6.34M |
|
$2.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.01M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.25% |
|
-6.25% |
|
-4.74% |
|
-6.25% |
|
$0.74 |
|
$-0.26 |
|
$-0.25 |
|